TTR and amyloidosis: The APOLLO study examines the efficacy and safety of the investigational RNAi therapeutic patisiran in a broad hATTR amyloidosis population, including patients with any amyloidogenic TTR mutation and with a wide range of neuropathy severity and age at baseline.